Alpha Tau Medical shares are trading lower. The company announced overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound-guided intratumoral Alpha DaRT treatment in patients with pancreatic ductal adenocarcinoma.